Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma

Table 1 Summary of study cases and samples

#	Stage	NACT cycles^a	CA-125 Response^b	Residual Disease at Interval Surgery	Time to Recurrence^c	Time to Death^d	Tumor Samples (ID)
1	IIIa	5 (9)	81 (84%)	0 cm	4.6 (Resistant)	21.4 (DOD)	Pre: omental biopsy *(1-1)^a,b Post:* pelvic nodule *(1-2)^a, omentum (1-3)*^b
2	IIIc	5 (5)	180 (62%)	> 1 cm	4.4 (Resistant)	12.1 (DOD)	Pre: omental biopsy *(2-1)^a,b Post:* omentum *(2-2)*^a,b
3	IIIb	4 (7)	96 (82%)	0 cm	3.6 (Resistant)	18.1 (DOD)	Pre: omental biopsy *(3-1)^a,b Post:* right ovary *(3-2)^a,b, omentum (3-3)*^a,b
4	IIIb	3 (6)	1634 (98%)	> 1 cm	19.5 (Sensitive)	47.9 (AWD)	Pre: omental biopsy *(4-1)^a,b Post:* stomach nodule *(4-2)*^a,b
5	IIIc	3 (6)	4659 (96%)	< 1 cm	20.9 (Sensitive)	42.2 (AWD)	Pre: biopsy (not specified) *(5-1)^a Post:* bowel nodule *(5-2)*^a

All patients had stage IIIa-c high-grade serous ovarian carcinoma that was treated with neo-adjuvant intravenous Carboplatin/Taxol chemotherapy (NACT) prior to interval cytoreductive surgery. Tumor samples were obtained at diagnosis (prior to NACT, “Pre”) and at surgery (after 3-5 cycles of NACT, “Post”). Buffy coat samples served as normal controls
^atotal first-line cycles indicated in brackets
^bCA-125 levels prior to the first cycle of NACT, with the percentage decrease after NACT indicated in brackets
^ctime to recurrence is shown in months and is based on the first observation of radiologic progression, typically with a concomitant or preceding rise in serum CA-125
^dtime to death or last follow-up is shown in months, with final status in brackets (“DOD” = dead of disease, “AWD” = alive with disease). Neither of the platinum-sensitive cases had developed platinum-resistant disease at last follow-up
Tumor sample sites included in whole exome sequencing (“a”) and targeted deep sequencing (“b”) are indicated

ISSN: 1757-2215